Significance and therapeutic value of miRNAs in embryonal neural tumors

Molecules

Volumn 19, Issue 5, 2014, Pages 5821-5862

  Shalaby, Tarek ^a   Fiaschetti, Giulio ^a   Baumgartner, Martin ^a   Grotzer, Michael A ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

AT RT; Embryonal tumors; Medulloblastoma; MicroRNAs; Neuroblastoma; SPNET

Indexed keywords

MICRORNA;

CHILD; DIAGNOSTIC USE; EARLY DIAGNOSIS; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GERM CELL AND EMBRYONAL; NERVOUS SYSTEM NEOPLASMS; PATHOLOGY; PROGNOSIS;

CHILD; EARLY DETECTION OF CANCER; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GERM CELL AND EMBRYONAL; NERVOUS SYSTEM NEOPLASMS; PROGNOSIS;

EID: 84901388051     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19055821     Document Type: Review

References (266)

1. Shalaby T.; Hiyama E.; Grotzer M.A. Telomere maintenance as therapeutic target in embryonal tumours. Anticancer Agents Med. Chem. 2010, 10, 196-212.
2. Grimmer M.R.; Weiss W.A. Childhood tumors of the nervous system as disorders of normal development. Curr. Opin. Pediatr. 2006, 18, 634-638.
3. Wu W. Modulation of microRNAs for potential cancer therapeutics. Methods Mol. Biol. 2011, 676, 59-70.
4. Hatfield S.D.; Shcherbata H.R.; Fischer K.A.; Nakahara K.; Carthew R.W.; Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature 2005, 435, 974-978.
5. Jin Z.; Xie T. Dcr-1 maintains Drosophila ovarian stem cells. Curr. Biol. 2007, 17, 539-544.
6. Kanellopoulou C.; Muljo S.A.; Kung A.L.; Ganesan S.; Drapkin R.; Jenuwein T.; Livingston D.M.; Rajewsky K. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev. 2005, 19, 489-501.
7. Murchison E.P.; Partridge J.F.; Tam O.H.; Cheloufi S.; Hannon G.J. Characterization of Dicerdeficient murine embryonic stem cells. Proc. Natl. Acad. Sci. USA 2005, 102, 12135-12140.
8. Park J.K.; Liu X.; Strauss T.J.; McKearin D.M.; Liu Q. The miRNA pathway intrinsically controls self-renewal of Drosophila germline stem cells. Curr. Biol. 2007, 17, 533-538.
9. Tran N.; McLean T.; Zhang X.; Zhao C.J.; Thomson J.M.; O'Brien C.; Rose B. MicroRNA expression profiles in head and neck cancer cell lines. Biochem. Biophys. Res. Commun. 2007, 358, 12-17.
10. Calin G.A.; Croce C.M. Chronic lymphocytic leukemia: Interplay between noncoding RNAs and protein-coding genes. Blood 2009, 114, 4761-4770.
11. He H.; Jazdzewski K.; Li W.; Liyanarachchi S.; Nagy R.; Volinia S.; Calin G.A.; Liu C.G.; Franssila K.; Suster S.; et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA 2005, 102, 19075-19080.
12. Si M.L.; Zhu S.; Wu H.; Lu Z.; Wu F.; Mo Y.Y. miR-21-mediated tumor growth. Oncogene 2007, 26, 2799-2803.
13. Corcoran C.; Friel A.M.; Duffy M.J.; Crown J.; O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin. Chem. 2011, 57, 18-32.
14. Zhu R.; Ji Y.; Xiao L.; Matin A. Testicular germ cell tumor susceptibility genes from the consomic 129.MOLF-Chr19 mouse strain. Mamm. Genome 2007, 18, 584-595.
15. Voorhoeve P.M.; le Sage C.; Schrier M.; Gillis A.J.; Stoop H.; Nagel R.; Liu Y.P.; van Duijse J.; Drost J.; Griekspoor A.; et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124, 1169-1181.
16. King C.E.; Wang L.; Winograd R.; Madison B.B.; Mongroo P.S.; Johnstone C.N.; Rustgi A.K. LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene 2011, 30, 4185-4193.
17. De Krijger I.; Mekenkamp L.J.; Punt C.J.; Nagtegaal I.D. MicroRNAs in colorectal cancer metastasis. J. Pathol. 2011, 224, 438-447.
18. Murray M.Y.; Rushworth S.A.; Macewan D.J. MicroRNAs as a new therapeutic target towards leukaemia signalling. Cell. Signal. 2012, 24, 363-368.
19. Lv M.; Zhang X.; Jia H.; Li D.; Zhang B.; Zhang H.; Hong M.; Jiang T.; Jiang Q.; Lu J.; et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-Alpha and cAMP/PKA pathways. Leukemia 2012, 26, 769-777.
20. Zhu W.; Liu X.; He J.; Chen D.; Hunag Y.; Zhang Y.K. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: A case control study. BMC Cancer 2011, 11, 393, doi:10.1186/1471-2407-11-393.
21. Lin P.Y.; Yu S.L.; Yang P.C. MicroRNA in lung cancer. Br. J. Cancer 2010, 103, 1144-1148.
22. Yu F.; Yao H.; Zhu P.; Zhang X.; Pan Q.; Gong C.; Huang Y.; Hu X.; Su F.; Lieberman J.; et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131, 1109-1123.
23. Hatfield S.; Ruohola-Baker H. microRNA and stem cell function. Cell Tissue Res. 2008, 331, 57-66.
24. Croce C.M.; Calin G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122, 6-7.
25. Silber J.; Lim D.A.; Petritsch C.; Persson A.I.; Maunakea A.K.; Yu M.; Vandenberg S.R.; Ginzinger D.G.; James C.D.; Costello J.F.; et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008, 6, 14, doi:10.1186/1741-7015-6-14.
26. DeSano J.T.; Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 2009, 11, 682-692.
27. Ferretti E.; de Smaele E.; Miele E.; Laneve P.; Po A.; Pelloni M.; Paganelli A.; di Marcotullio L.; Caffarelli E.; Screpanti I.; et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008, 27, 2616-2627.
28. Legler J.M.; Ries L.A.; Smith M.A.; Warren J.L.; Heineman E.F.; Kaplan R.S.; Linet M.S. Cancer surveillance series [corrected]: Brain and other central nervous system cancers: Recent trends in incidence and mortality. J. Natl. Cancer Inst. 1999, 91, 1382-1390.
29. Louis D.N.; Ohgaki H.; Wiestler O.D.; Cavenee W.K.; Burger P.C.; Jouvet A.; Scheithauer B.W.; Kleihues P. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. (Berl.) 2007, 114, 97-109.
30. Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
31. Calin G.A.; Sevignani C.; Dumitru C.D.; Hyslop T.; Noch E.; Yendamuri S.; Shimizu M.; Rattan S.; Bullrich F.; Negrini M.; et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999-3004.
32. Palmero E.I.; de Campos S.G.; Campos M.; de Souza N.C.; Guerreiro I.D.; Carvalho A.L.; Marques M.M. Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet. Mol. Biol. 2011, 34, 363-370.
33. Esquela-Kerscher A.; Slack F.J. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259-269.
34. Calin G.A.; Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
35. Medina P.P.; Slack F.J. microRNAs and cancer: An overview. Cell Cycle 2008, 7, 2485-2492.
36. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10, 704-714.
37. Navarro A.; Monzo M. MicroRNAs in human embryonic and cancer stem cells. Yonsei Med. J. 2010, 51, 622-632.
38. Zhao B.; Huang B.; Li W.; Jin Y. MicroRNA expression profiling during neural differentiation of mouse embryonic carcinoma P19 cells. Methods Mol. Biol. 2013, 936, 105-116.
39. Lakshmipathy U.; Davila J.; Hart R.P. miRNA in pluripotent stem cells. Regen. Med. 2010, 5, 545-555.
40. Yekta S.; Shih I.H.; Bartel D.P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004, 304, 594-596.
41. Visvanathan J.; Lee S.; Lee B.; Lee J.W.; Lee S.K. The microRNA miR-124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS development. Genes Dev. 2007, 21, 744-749.
42. Suh M.R.; Lee Y.; Kim J.Y.; Kim S.K.; Moon S.H.; Lee J.Y.; Cha K.Y.; Chung H.M.; Yoon H.S.; Moon S.Y.; et al. Human embryonic stem cells express a unique set of microRNAs. Dev. Biol. 2004, 270, 488-498.
43. Slack F.J. Stem cells: Big roles for small RNAs. Nature 2010, 463, 616, doi:10.1038/463616a.
44. Makeyev E.V.; Zhang J.; Carrasco M.A.; Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell 2007, 27, 435-448.
45. Houbaviy H.B.; Murray M.F.; Sharp P.A. Embryonic stem cell-specific MicroRNAs. Dev. Cell 2003, 5, 351-358.
46. Cao X.; Yeo G.; Muotri A.R.; Kuwabara T.; Gage F.H. Noncoding RNAs in the mammalian central nervous system. Annu. Rev. Neurosci. 2006, 29, 77-103.
47. Cao X.; Pfaff S.L.; Gage F.H. A functional study of miR-124 in the developing neural tube. Genes Dev. 2007, 21, 531-536.
48. Viswanathan S.R.; Daley G.Q.; Gregory R.I. Selective blockade of microRNA processing by Lin28. Science 2008, 320, 97-100.
49. Morin R.D.; O'Connor M.D.; Griffith M.; Kuchenbauer F.; Delaney A.; Prabhu A.L.; Zhao Y.; McDonald H.; Zeng T.; Hirst M.; et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res. 2008, 18, 610-621.
50. Mineno J.; Okamoto S.; Ando T.; Sato M.; Chono H.; Izu H.; Takayama M.; Asada K.; Mirochnitchenko O.; Inouye M.; et al. The expression profile of microRNAs in mouse embryos. Nucleic Acids Res. 2006, 34, 1765-1771.
51. Lee C.T.; Risom T.; Strauss W.M. MicroRNAs in mammalian development. Birth Defects Res. C Embryo Today 2006, 78, 129-139.
52. Goff L.A.; Davila J.; Swerdel M.R.; Moore J.C.; Cohen R.I.; Wu H.; Sun Y.E.; Hart R.P. Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS One 2009, 4, e7192.
53. Gangaraju V.K.; Lin H. MicroRNAs: Key regulators of stem cells. Nat. Rev. Mol. Cell Biol. 2009, 10, 116-125.
54. Bar M.; Wyman S.K.; Fritz B.R.; Qi J.; Garg K.S.; Parkin R.K.; Kroh E.M.; Bendoraite A.; Mitchell P.S.; Nelson A.M.; et al. MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries. Stem Cells 2008, 26, 2496-2505.
55. Coolen M.; Bally-Cuif L. MicroRNAs in brain development and physiology. Curr. Opin. Neurobiol. 2009, 19, 461-470.
56. Kapsimali M.; Kloosterman W.P.; de Bruijn E.; Rosa F.; Plasterk R.H.; Wilson S.W. MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol. 2007, 8, R173, doi:10.1186/gb-2007-8-8-r173.
57. Giraldez A.J.; Cinalli R.M.; Glasner M.E.; Enright A.J.; Thomson J.M.; Baskerville S.; Hammond S.M.; Bartel D.P.; Schier A.F. MicroRNAs regulate brain morphogenesis in zebrafish. Science 2005, 308, 833-838.
58. Zhao C.; Sun G.; Li S.; Shi Y. A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. Nat. Struct. Mol. Biol. 2009, 16, 365-371.
59. Yu J.Y.; Chung K.H.; Deo M.; Thompson R.C.; Turner D.L. MicroRNA miR-124 regulates neurite outgrowth during neuronal differentiation. Exp. Cell Res. 2008, 314, 2618-2633.
60. Sempere L.F.; Freemantle S.; Pitha-Rowe I.; Moss E.; Dmitrovsky E.; Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004, 5, R13, doi:10.1186/gb-2004-5-3-r13.
61. Packer A.N.; Xing Y.; Harper S.Q.; Jones L.; Davidson B.L. The bifunctional microRNA miR-9/miR-9 regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 2008, 28, 14341-14346.
62. Miska E.A.; Alvarez-Saavedra E.; Townsend M.; Yoshii A.; Sestan N.; Rakic P.; Constantine-Paton M.; Horvitz H.R. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 2004, 5, R68, doi:10.1186/gb-2004-5-9-r68.
63. Landgraf P.; Rusu M.; Sheridan R.; Sewer A.; Iovino N.; Aravin A.; Pfeffer S.; Rice A.; Kamphorst A.O.; Landthaler M.; et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129, 1401-1414.
64. Kim J.; Inoue K.; Ishii J.; Vanti W.B.; Voronov S.V.; Murchison E.; Hannon G.; Abeliovich A. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317, 1220-1224.
65. Conaco C.; Otto S.; Han J.J.; Mandel G. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc. Natl. Acad. Sci. USA 2006, 103, 2422-2427.
66. Choi P.S.; Zakhary L.; Choi W.Y.; Caron S.; Alvarez-Saavedra E.; Miska E.A.; McManus M.; Harfe B.; Giraldez A.J.; Horvitz H.R.; et al. Members of the miRNA-200 family regulate olfactory neurogenesis. Neuron 2008, 57, 41-55.
67. Cheng L.C.; Pastrana E.; Tavazoie M.; Doetsch F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat. Neurosci. 2009, 12, 399-408.
68. Kim J.; Krichevsky A.; Grad Y.; Hayes G.D.; Kosik K.S.; Church G.M.; Ruvkun G. Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc. Natl. Acad. Sci. USA 2004, 101, 360-365.
69. Fernandez L.A.; Northcott P.A.; Taylor M.D.; Kenney A.M. Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle 2009, 8, 4049-4054.
70. Zhao C.; Deng W.; Gage F.H. Mechanisms and functional implications of adult neurogenesis. Cell 2008, 132, 645-660.
71. Lin S.L.; Chang D.C.; Chang-Lin S.; Lin C.H.; Wu D.T.; Chen D.T.; Ying S.Y. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008, 14, 2115-2124.
72. Singh S.K.; Hawkins C.; Clarke I.D.; Squire J.A.; Bayani J.; Hide T.; Henkelman R.M.; Cusimano M.D.; Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401.
73. Singh S.K.; Clarke I.D.; Terasaki M.; Bonn V.E.; Hawkins C.; Squire J.; Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828.
74. Yang Z.J.; Ellis T.; Markant S.L.; Read T.A.; Kessler J.D.; Bourboulas M.; Schuller U.; Machold R.; Fishell G.; Rowitch D.H.; et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008, 14, 135-145.
75. Fan X.; Eberhart C.G. Medulloblastoma stem cells. J. Clin. Oncol. 2008, 26, 2821-2827.
76. Mantamadiotis T.; Taraviras S. Self-renewal mechanisms in neural cancer stem cells. Front. Biosci. 2011, 16, 598-607.
77. Gurney J.G.; Smith M.A.; Bunin G.R. CNS and miscellaneous intracranial and intraspinal neoplasms. In Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995; Ries L.A.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L., Bunin G.R., Eds.; National Institutes of Health: Bethesda, MD, USA, 1999; pp. 51-63.
78. Giangaspero F.; Perilongo G.; Fondelli M.P.; Brisigotti M.; Carollo C.; Burnelli R.; Burger P.C.; Garre M.L. Medulloblastoma with extensive nodularity: A variant with favorable prognosis. J. Neurosurg. 1999, 91, 971-977.
79. McManamy C.S.; Pears J.; Weston C.L.; Hanzely Z.; Ironside J.W.; Taylor R.E.; Grundy R.G.; Clifford S.C.; Ellison D.W. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol. 2007, 17, 151-164.
80. Pfister S.; Remke M.; Benner A.; Mendrzyk F.; Toedt G.; Felsberg J.; Wittmann A.; Devens F.; Gerber N.U.; Joos S.; et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 2009, 27, 1627-1636.
81. Thompson M.C.; Fuller C.; Hogg T.L.; Dalton J.; Finkelstein D.; Lau C.C.; Chintagumpala M.; Adesina A.; Ashley D.M.; Kellie S.J.; et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 2006, 24, 1924-1931.
82. Kool M.; Koster J.; Bunt J.; Hasselt N.E.; Lakeman A.; van Sluis P.; Troost D.; Meeteren N.S.; Caron H.N.; Cloos J.; et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008, 3, e3088.
83. Pfister S.M.; Korshunov A.; Kool M.; Hasselblatt M.; Eberhart C.; Taylor M.D. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol. 2010, 120, 553-566.
84. Northcott P.A.; Korshunov A.; Witt H.; Hielscher T.; Eberhart C.G.; Mack S.; Bouffet E.; Clifford S.C.; Hawkins C.E.; French P.; et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 2011, 29, 1408-1414.
85. Kool M.; Korshunov A.; Remke M.; Jones D.T.; Schlanstein M.; Northcott P.A.; Cho Y.J.; Koster J.; Schouten-van Meeteren A.; van Vuurden D.; et al. Molecular subgroups of medulloblastoma: An international meta-Analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012, 123, 473-484.
86. Remke M.; Hielscher T.; Korshunov A.; Northcott P.A.; Bender S.; Kool M.; Westermann F.; Benner A.; Cin H.; Ryzhova M.; et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J. Clin. Oncol. 2011, 29, 3852-3861.
87. Taylor M.D.; Northcott P.A.; Korshunov A.; Remke M.; Cho Y.J.; Clifford S.C.; Eberhart C.G.; Parsons D.W.; Rutkowski S.; Gajjar A.; et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol. 2012, 123, 465-472.
88. Pierson J.; Hostager B.; Fan R.; Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J. Neuro-Oncol. 2008, 90, 1-7.
89. Mendrzyk F.; Radlwimmer B.; Joos S.; Kokocinski F.; Benner A.; Stange D.E.; Neben K.; Fiegler H.; Carter N.P.; Reifenberger G.; et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J. Clin. Oncol. 2005, 23, 8853-8862.
90. Northcott P.A.; Fernandez L.A.; Hagan J.P.; Ellison D.W.; Grajkowska W.; Gillespie Y.; Grundy R.; van Meter T.; Rutka J.T.; Croce C.M.; et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-Treated cerebellar neural precursors. Cancer Res. 2009, 69, 3249-3255.
91. Pang J.C.; Kwok W.K.; Chen Z.; Ng H.K. Oncogenic role of microRNAs in brain tumors. Acta Neuropathol. 2009, 117, 599-611.
92. Ciafre S.A.; Galardi S.; Mangiola A.; Ferracin M.; Liu C.G.; Sabatino G.; Negrini M.; Maira G.; Croce C.M.; Farace M.G. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 2005, 334, 1351-1358.
93. Turner J.D.; Williamson R.; Almefty K.K.; Nakaji P.; Porter R.; Tse V.; Kalani M.Y. The many roles of microRNAs in brain tumor biology. Neurosurg. Focus 2010, 28, E3, doi:10.3171/2009.10.FOCUS09207.
94. Laneve P.; Di Marcotullio L.; Gioia U.; Fiori M.E.; Ferretti E.; Gulino A.; Bozzoni I.; Caffarelli E. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc. Natl. Acad. Sci. USA 2007, 104, 7957-7962.
95. Birks D.K.; Barton V.N.; Donson A.M.; Handler M.H.; Vibhakar R.; Foreman N.K. Survey of MicroRNA expression in pediatric brain tumors. Pediatr. Blood Cancer 2011, 56, 211-216.
96. Ma L.; Weinberg R.A. Micromanagers of malignancy: Role of microRNAs in regulating metastasis. Trends Genet. 2008, 24, 448-456.
97. Ventura A.; Jacks T. MicroRNAs and cancer: Short RNAs go a long way. Cell 2009, 136, 586-591.
98. White N.M.; Fatoohi E.; Metias M.; Jung K.; Stephan C.; Yousef G.M. Metastamirs: A stepping stone towards improved cancer management. Nat. Rev. Clin. Oncol. 2011, 8, 75-84.
99. Asangani I.A.; Rasheed S.A.; Nikolova D.A.; Leupold J.H.; Colburn N.H.; Post S.; Allgayer H. MicroRNA-21 (miR-21) post-Transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27, 2128-2136.
100. Grunder E.; D'Ambrosio R.; Fiaschetti G.; Abela L.; Arcaro A.; Zuzak T.; Ohgaki H.; Lv S.Q.; Shalaby T.; Grotzer M. MicroRNA-21 suppression impedes medulloblastoma cell migration. Eur. J. Cancer 2011, 47, 2479-2490.
101. Ajeawung N.F.; Li B.; Kamnasaran D. Translational applications of microRNA genes in medulloblastomas. Clin. Investig. Med. 2010, 33, E223-E233.
102. Mei H.; Lin Z.Y.; Tong Q.S. The roles of microRNAs in neuroblastoma. World J. Pediatr. 2014, 10, 10-16.
103. Spence T.N.J.; Bouffet E.; Huang A.; Cho W.C.S. MicroRNAs in Brain Tumors; Springer Netherlands: Dordrecht, The Netherlands, 2011.
104. Zollo M.; Andolfo I.; de Antonellis P. MicroRNAs and Cancer Stem Cells in Medulloblastoma; Shostak S., Ed.; InTech: Rijeka, Croatia, 2011.
105. Dews M.; Homayouni A.; Yu D.; Murphy D.; Sevignani C.; Wentzel E.; Furth E.E.; Lee W.M.; Enders G.H.; Mendell J.T.; et al. Augmentation of tumor angiogenesis by a Myc-Activated microRNA cluster. Nat. Genet. 2006, 38, 1060-1065.
106. Mavrakis K.J.; Wolfe A.L.; Oricchio E.; Palomero T.; de Keersmaecker K.; McJunkin K.; Zuber J.; James T.; Khan A.A.; Leslie C.S.; et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat. Cell Biol. 2010, 12, 372-379.
107. Ferretti E.; de Smaele E.; Po A.; di Marcotullio L.; Tosi E.; Espinola M.S.; di Rocco C.; Riccardi R.; Giangaspero F.; Farcomeni A.; et al. MicroRNA profiling in human medulloblastoma. Int. J. Cancer 2009, 124, 568-577.
108. Roush S.; Slack F.J. The let-7 family of microRNAs. Trends Cell Biol. 2008, 18, 505-516.
109. Garzia L.; Andolfo I.; Cusanelli E.; Marino N.; Petrosino G.; de Martino D.; Esposito V.; Galeone A.; Navas L.; Esposito S.; et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 2009, 4, e4998.
110. Weeraratne S.D.; Amani V.; Neiss A.; Teider N.; Scott D.K.; Pomeroy S.L.; Cho Y.J. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro-Oncology 2011, 13, 165-175.
111. Fiaschetti G.; Abela L.; Nonoguchi N.; Dubuc A.M.; Remke M.; Boro A.; Grunder E.; Siler U.; Ohgaki H.; Taylor M.D.; et al. Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma. Br. J. Cancer 2014, 110, 636-647.
112. Kefas B.; Godlewski J.; Comeau L.; Li Y.; Abounader R.; Hawkinson M.; Lee J.; Fine H.; Chiocca E.A.; Lawler S.; et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68, 3566-3572.
113. Li K.K.; Pang J.C.; Ching A.K.; Wong C.K.; Kong X.; Wang Y.; Zhou L.; Chen Z.; Ng H.K. miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum. Pathol. 2009, 40, 1234-1243.
114. Yoo A.S.; Staahl B.T.; Chen L.; Crabtree G.R. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 2009, 460, 642-646.
115. Lu Y.; Ryan S.L.; Elliott D.J.; Bignell G.R.; Futreal P.A.; Ellison D.W.; Bailey S.; Clifford S.C. Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One 2009, 4, e6159.
116. Liu W.; Gong Y.H.; Chao T.F.; Peng X.Z.; Yuan J.G.; Ma Z.Y.; Jia G.; Zhao J.Z. Identification of differentially expressed microRNAs by microarray: A possible role for microRNAs gene in medulloblastomas. Chin. Med. J. 2009, 122, 2405-2411.
117. Wei J.S.; Johansson P.; Chen Q.R.; Song Y.K.; Durinck S.; Wen X.; Cheuk A.T.; Smith M.A.; Houghton P.; Morton C.; et al. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin. Cancer Res. 2009, 15, 5560-5568.
118. Venkataraman S.; Alimova I.; Fan R.; Harris P.; Foreman N.; Vibhakar R. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One 2010, 5, e10748.
119. Weeraratne S.D.; Amani V.; Teider N.; Pierre-Francois J.; Winter D.; Kye M.J.; Sengupta S.; Archer T.; Remke M.; Bai A.H.; et al. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012, 123, 539-552.
120. Gokhale A.; Kunder R.; Goel A.; Sarin R.; Moiyadi A.; Shenoy A.; Mamidipally C.; Noronha S.; Kannan S.; Shirsat N.V. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J. Cancer Res. Ther. 2010, 6, 521-529.
121. Li M.; Lee K.F.; Lu Y.; Clarke I.; Shih D.; Eberhart C.; Collins V.P.; van Meter T.; Picard D.; Zhou L.; et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009, 16, 533-546.
122. Wang F.; Xue X.; Wei J.; An Y.; Yao J.; Cai H.; Wu J.; Dai C.; Qian Z.; Xu Z.; et al. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br. J. Cancer 2010, 103, 567-574.
123. Sredni S.T.; Bonaldo Mde F.; Costa F.F.; Huang C.C.; Hamm C.A.; Rajaram V.; Tomita T.; Goldman S.; Bischof J.M.; Soares M.B. Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: Potential therapeutic targets. Childs Nerv. Syst. 2010, 26, 279-283.
124. Zhang K.; Gao H.; Wu X.; Wang J.; Zhou W.; Sun G.; Wang J.; Wang Y.; Mu B.; Kim C.; et al. Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA. Clin. Cancer Res. 2014, 20, 1179-1189.
125. Schulte J.H.; Marschall T.; Martin M.; Rosenstiel P.; Mestdagh P.; Schlierf S.; Thor T.; Vandesompele J.; Eggert A.; Schreiber S.; et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res. 2010, 38, 5919-5928.
126. De Brouwer S.; Mestdagh P.; Lambertz I.; Pattyn F.; de Paepe A.; Westermann F.; Schroeder C.; Schulte J.H.; Schramm A.; de Preter K.; et al. Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. Int. J. Cancer 2012, 130, 2591-2598.
127. Stallings R.L. MicroRNA involvement in the pathogenesis of neuroblastoma: Potential for microRNA mediated therapeutics. Curr. Pharm. Des. 2009, 15, 456-462.
128. Mestdagh P.; Fredlund E.; Pattyn F.; Schulte J.H.; Muth D.; Vermeulen J.; Kumps C.; Schlierf S.; de Preter K.; van Roy N.; et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-Activated tumors. Oncogene 2010, 29, 1394-1404.
129. Chen Y.; Tsai Y.H.; Fang Y.; Tseng S.H. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J. Pediatr. Surg. 2012, 47, 1797-1805.
130. Huang T.C.; Chang H.Y.; Chen C.Y.; Wu P.Y.; Lee H.; Liao Y.F.; Hsu W.M.; Huang H.C.; Juan H.F. Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR. FEBS Lett. 2011, 585, 3582-3586.
131. Mestdagh P.; Bostrom A.K.; Impens F.; Fredlund E.; van Peer G.; de Antonellis P.; von Stedingk K.; Ghesquiere B.; Schulte S.; Dews M.; et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol. Cell 2010, 40, 762-773.
132. Swarbrick A.; Woods S.L.; Shaw A.; Balakrishnan A.; Phua Y.; Nguyen A.; Chanthery Y.; Lim L.; Ashton L.J.; Judson R.L.; et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-Amplified neuroblastoma. Nat. Med. 2010, 16, 1134-1140.
133. Xin C.; Buhe B.; Hongting L.; Chuanmin Y.; Xiwei H.; Hong Z.; Lulu H.; Qian D.; Renjie W. MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression. FEBS J. 2013, 280, 855-866.
134. Schulte J.H.; Horn S.; Schlierf S.; Schramm A.; Heukamp L.C.; Christiansen H.; Buettner R.; Berwanger B.; Eggert A. MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett. 2009, 274, 10-15.
135. Tivnan A.; Foley N.H.; Tracey L.; Davidoff A.M.; Stallings R.L. MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res. 2010, 30, 4391-4395.
136. Evangelisti C.; Florian M.C.; Massimi I.; Dominici C.; Giannini G.; Galardi S.; Bue M.C.; Massalini S.; McDowell H.P.; Messi E.; et al. MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J. 2009, 23, 4276-4287.
137. Gattolliat C.H.; Thomas L.; Ciafre S.A.; Meurice G.; Le Teuff G.; Job B.; Richon C.; Combaret V.; Dessen P.; Valteau-Couanet D.; et al. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br. J. Cancer 2011, 105, 1352-1361.
138. Cole K.A.; Attiyeh E.F.; Mosse Y.P.; Laquaglia M.J.; Diskin S.J.; Brodeur G.M.; Maris J.M. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res. 2008, 6, 735-742.
139. Chen Y.; Tsai Y.H.; Tseng S.H. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN- survivin pathway. Surgery 2013, 153, 4-16.
140. Bray I.; Tivnan A.; Bryan K.; Foley N.H.; Watters K.M.; Tracey L.; Davidoff A.M.; Stallings R.L. MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett. 2011, 303, 56-64.
141. Buechner J.; Tomte E.; Haug B.H.; Henriksen J.R.; Lokke C.; Flaegstad T.; Einvik C. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-Amplified neuroblastoma. Br. J. Cancer 2011, 105, 296-303.
142. Afanasyeva E.A.; Mestdagh P.; Kumps C.; Vandesompele J.; Ehemann V.; Theissen J.; Fischer M.; Zapatka M.; Brors B.; Savelyeva L.; et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ. 2011, 18, 974-984.
143. Lee J.J.; Drakaki A.; Iliopoulos D.; Struhl K. MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 2012, 31, 3818-3825.
144. Chakrabarti M.; Banik N.L.; Ray S.K. miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo. Exp. Cell Res. 2013, 319, 1575-1585.
145. Althoff K.; Beckers A.; Odersky A.; Mestdagh P.; Koster J.; Bray I.M.; Bryan K.; Vandesompele J.; Speleman F.; Stallings R.L.; et al. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int. J. Cancer 2013, 133, 1064-1073.
146. Ryan J.; Tivnan A.; Fay J.; Bryan K.; Meehan M.; Creevey L.; Lynch J.; Bray I.M.; O'Meara A.; Davidoff A.M.; et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br. J. Cancer 2012, 107, 967-976.
147. Slaby O. MiR-190 leads to aggressive phenotype of neuroblastoma through indirect activation of TrkB pathway. Med. Hypotheses 2013, 80, 325-326.
148. Foley N.H.; Bray I.; Watters K.M.; Das S.; Bryan K.; Bernas T.; Prehn J.H.; Stallings R.L. MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ. 2011, 18, 1089-1098.
149. Qiao J.; Lee S.; Paul P.; Theiss L.; Tiao J.; Qiao L.; Kong A.; Chung D.H. miR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis. Surgery 2013, 154, 226-233.
150. Lynch J.; Fay J.; Meehan M.; Bryan K.; Watters K.M.; Murphy D.M.; Stallings R.L. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 2012, 33, 976-985.
151. Zhang H.; Qi M.; Li S.; Qi T.; Mei H.; Huang K.; Zheng L.; Tong Q. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol. Cancer Ther. 2012, 11, 1454-1466.
152. Zhang H.; Pu J.; Qi T.; Qi M.; Yang C.; Li S.; Huang K.; Zheng L.; Tong Q. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene 2014, 33, 387-397.
153. Guo J.; Dong Q.; Fang Z.; Chen X.; Lu H.; Wang K.; Yin Y.; Cai X.; Zhao N.; Chen J.; et al. Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol. Ther. 2010, 9, 446-452.
154. Loven J.; Zinin N.; Wahlstrom T.; Muller I.; Brodin P.; Fredlund E.; Ribacke U.; Pivarcsi A.; Pahlman S.; Henriksson M. MYCN-regulated microRNAs repress estrogen receptor-Alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc. Natl. Acad. Sci. USA 2010, 107, 1553-1558.
155. Schulte J.H.; Schowe B.; Mestdagh P.; Kaderali L.; Kalaghatgi P.; Schlierf S.; Vermeulen J.; Brockmeyer B.; Pajtler K.; Thor T.; et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int. J. Cancer 2010, 127, 2374-2385.
156. Bienertova-Vasku J.; Mazanek P.; Hezova R.; Curdova A.; Nekvindova J.; Kren L.; Sterba J.; Slaby O. Extension of microRNA expression pattern associated with high-risk neuroblastoma. Tumour Biol. 2013, 34, 2315-2319.
157. Lin R.J.; Lin Y.C.; Chen J.; Kuo H.H.; Chen Y.Y.; Diccianni M.B.; London W.B.; Chang C.H.; Yu A.L. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010, 70, 7841-7850.
158. De Preter K.; Mestdagh P.; Vermeulen J.; Zeka F.; Naranjo A.; Bray I.; Castel V.; Chen C.; Drozynska E.; Eggert A.; et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin. Cancer Res. 2011, 17, 7684-7692.
159. Buckley P.G.; Alcock L.; Bryan K.; Bray I.; Schulte J.H.; Schramm A.; Eggert A.; Mestdagh P.; de Preter K.; Vandesompele J.; et al. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma. Clin. Cancer Res. 2010, 16, 2971-2978.
160. Kunder R.; Jalali R.; Sridhar E.; Moiyadi A.; Goel N.; Goel A.; Gupta T.; Krishnatry R.; Kannan S.; Kurkure P.; et al. Real-Time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro-Oncology 2013, 15, 1644-1651.
161. Chan J.A.; Krichevsky A.M.; Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65, 6029-6033.
162. Uziel T.; Karginov F.V.; Xie S.; Parker J.S.; Wang Y.D.; Gajjar A.; He L.; Ellison D.; Gilbertson R.J.; Hannon G.; et al. The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc. Natl. Acad. Sci. USA 2009, 106, 2812-2817.
163. Northcott P.A.; Nakahara Y.; Wu X.; Feuk L.; Ellison D.W.; Croul S.; Mack S.; Kongkham P.N.; Peacock J.; Dubuc A.; et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat. Genet. 2009, 41, 465-472.
164. Murphy B.L.; Obad S.; Bihannic L.; Ayrault O.; Zindy F.; Kauppinen S.; Roussel M.F. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013, 73, 7068-7078.
165. Roussel M.F.; Robinson G.W. Role of MYC in Medulloblastoma. Cold Spring Harb. Perspect. Med. 2013, 3, doi:10.1101/cshperspect.a014308.
166. Bai A.H.; Milde T.; Remke M.; Rolli C.G.; Hielscher T.; Cho Y.J.; Kool M.; Northcott P.A.; Jugold M.; Bazhin A.V.; et al. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012, 123, 529-538.
167. Cho Y.J.; Tsherniak A.; Tamayo P.; Santagata S.; Ligon A.; Greulich H.; Berhoukim R.; Amani V.; Goumnerova L.; Eberhart C.G.; et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 2011, 29, 1424-1430.
168. Grunwald I.; Dillmann K.; Roth C.; Backens M.; Reith W. Supratentorial tumors. Radiologe 2007, 47, 471-485.
169. Allen J.C.; Judkins A.R.; Rosenblum M.K.; Biegel J.A. Atypical teratoid/rhabdoid tumor evolving from an optic pathway ganglioglioma: Case study. Neuro-Oncology 2006, 8, 79-82.
170. Li M.H.; Bouffet E.; Hawkins C.E.; Squire J.A.; Huang A. Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurg. Focus 2005, 19, E3.
171. Nobusawa S.; Yokoo H.; Hirato J.; Kakita A.; Takahashi H.; Sugino T.; Tasaki K.; Itoh H.; Hatori T.; Shimoyama Y.; et al. Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. Brain Pathol. 2012, 22, 689-697.
172. Korshunov A.; Remke M.; Gessi M.; Ryzhova M.; Hielscher T.; Witt H.; Tobias V.; Buccoliero A.M.; Sardi I.; Gardiman M.P.; et al. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol. 2010, 120, 253-260.
173. Kleinman C.L.; Gerges N.; Papillon-Cavanagh S.; Sin-Chan P.; Pramatarova A.; Quang D.A.; Adoue V.; Busche S.; Caron M.; Djambazian H.; et al. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat. Genet. 2014, 46, 39-44.
174. Archer T.C.; Pomeroy S.L. A developmental program drives aggressive embryonal brain tumors. Nat. Genet. 2014, 46, 2-3.
175. Rorke L.B.; Packer R.J.; Biegel J.A. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: Definition of an entity. J. Neurosurg. 1996, 85, 56-65.
176. Reddy A.T. Atypical teratoid/rhabdoid tumors of the central nervous system. J. Neuro-Oncol. 2005, 75, 309-313.
177. Oda Y.; Tsuneyoshi M. Extrarenal rhabdoid tumors of soft tissue: Clinicopathological and molecular genetic review and distinction from other soft-Tissue sarcomas with rhabdoid features. Pathol. Int. 2006, 56, 287-295.
178. Versteege I.; Sevenet N.; Lange J.; Rousseau-Merck M.F.; Ambros P.; Handgretinger R.; Aurias A.; Delattre O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998, 394, 203-206.
179. Biegel J.A.; Tan L.; Zhang F.; Wainwright L.; Russo P.; Rorke L.B. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin. Cancer Res. 2002, 8, 3461-3467.
180. Bambakidis N.C.; Robinson S.; Cohen M.; Cohen A.R. Atypical teratoid/rhabdoid tumors of the central nervous system: Clinical, radiographic and pathologic features. Pediatr. Neurosurg. 2002, 37, 64-70.
181. Hilden J.M.; Meerbaum S.; Burger P.; Finlay J.; Janss A.; Scheithauer B.W.; Walter A.W.; Rorke L.B.; Biegel J.A. Central nervous system atypical teratoid/rhabdoid tumor: Results of therapy in children enrolled in a registry. J. Clin. Oncol. 2004, 22, 2877-2884.
182. Tekautz T.M.; Fuller C.E.; Blaney S.; Fouladi M.; Broniscer A.; Merchant T.E.; Krasin M.; Dalton J.; Hale G.; Kun L.E.; et al. Atypical teratoid/rhabdoid tumors (ATRT): Improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J. Clin. Oncol. 2005, 23, 1491-1499.
183. Brodeur G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3, 203-216.
184. Maris J.M.; Hogarty M.D.; Bagatell R.; Cohn S.L. Neuroblastoma. Lancet 2007, 369, 2106-2120.
185. Schor N.F. Neuroblastoma as a neurobiological disease. J. Neuro-Oncol. 1999, 41, 159-166.
186. Evans A.E.; D'Angio G.J.; Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 1971, 27, 374-378.
187. Nakagawara A.; Ohira M. Comprehensive genomics linking between neural development and cancer: Neuroblastoma as a model. Cancer Lett. 2004, 204, 213-224.
188. Johnsen J.I.; Kogner P.; Albihn A.; Henriksson M.A. Embryonal neural tumours and cell death. Apoptosis 2009, 14, 424-438.
189. Jiang M.; Stanke J.; Lahti J.M. The connections between neural crest development and neuroblastoma. Curr. Top. Dev. Biol. 2011, 94, 77-127.
190. Maris J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr. 2005, 17, 7-13.
191. Bordow S.B.; Norris M.D.; Haber P.S.; Marshall G.M.; Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J. Clin. Oncol. 1998, 16, 3286-3294.
192. Cohn S.L.; London W.B.; Huang D.; Katzenstein H.M.; Salwen H.R.; Reinhart T.; Madafiglio J.; Marshall G.M.; Norris M.D.; Haber M. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol. 2000, 18, 3604-3613.
193. Chen Y.; Stallings R.L. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007, 67, 976-983.
194. Zhang H.; Li Y.; Lai M. The microRNA network and tumor metastasis. Oncogene 2010, 29, 937-948.
195. Gebeshuber C.A.; Zatloukal K.; Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 2009, 10, 400-405.
196. Buechner J.; Einvik C. N-myc and noncoding RNAs in neuroblastoma. Mol. Cancer Res. 2012, 10, 1243-1253.
197. Fontana L.; Fiori M.E.; Albini S.; Cifaldi L.; Giovinazzi S.; Forloni M.; Boldrini R.; Donfrancesco A.; Federici V.; Giacomini P.; et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008, 3, e2236.
198. Schulte J.H.; Horn S.; Otto T.; Samans B.; Heukamp L.C.; Eilers U.C.; Krause M.; Astrahantseff K.; Klein-Hitpass L.; Buettner R.; et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int. J. Cancer 2008, 122, 699-704.
199. Mestdagh P.; van Vlierberghe P.; de Weer A.; Muth D.; Westermann F.; Speleman F.; Vandesompele J. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009, 10, R64, doi:10.1186/gb-2009-10-6-r64.
200. Bray I.; Bryan K.; Prenter S.; Buckley P.G.; Foley N.H.; Murphy D.M.; Alcock L.; Mestdagh P.; Vandesompele J.; Speleman F.; et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: Association of miRNA expression with survival. PLoS One 2009, 4, e7850.
201. Shohet J.M.; Ghosh R.; Coarfa C.; Ludwig A.; Benham A.L.; Chen Z.; Patterson D.M.; Barbieri E.; Mestdagh P.; Sikorski D.N.; et al. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res. 2011, 71, 3841-3851.
202. Haug B.H.; Henriksen J.R.; Buechner J.; Geerts D.; Tomte E.; Kogner P.; Martinsson T.; Flaegstad T.; Sveinbjornsson B.; Einvik C. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis 2011, 32, 1005-1012.
203. Foley N.H.; Bray I.M.; Tivnan A.; Bryan K.; Murphy D.M.; Buckley P.G.; Ryan J.; O'Meara A.; O'Sullivan M.; Stallings R.L. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol. Cancer 2010, 9, 83, doi:10.1186/1476-4598-9-83.
204. Bian S.; Hong J.; Li Q.; Schebelle L.; Pollock A.; Knauss J.L.; Garg V.; Sun T. MicroRNA cluster miR-17-92 regulates neural stem cell expansion and transition to intermediate progenitors in the developing mouse neocortex. Cell Rep. 2013, 3, 1398-1406.
205. Cho W.C. MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 2010, 42, 1273-1281.
206. Mitchell P.S.; Parkin R.K.; Kroh E.M.; Fritz B.R.; Wyman S.K.; Pogosova-Agadjanyan E.L.; Peterson A.; Noteboom J.; O'Briant K.C.; Allen A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
207. White N.M.; Bao T.T.; Grigull J.; Youssef Y.M.; Girgis A.; Diamandis M.; Fatoohi E.; Metias M.; Honey R.J.; Stewart R.; et al. miRNA profiling for clear cell renal cell carcinoma: Biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J. Urol. 2011, 186, 1077-1083.
208. Heneghan H.M.; Miller N.; Kelly R.; Newell J.; Kerin M.J. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010, 15, 673-682.
209. Nass D.; Rosenwald S.; Meiri E.; Gilad S.; Tabibian-Keissar H.; Schlosberg A.; Kuker H.; Sion-Vardy N.; Tobar A.; Kharenko O.; et al. MiR-92b and miR-9/9 are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2009, 19, 375-383.
210. Osaki M.; Takeshita F.; Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 2008, 13, 658-670.
211. Wang J.; Chen J.; Chang P.; LeBlanc A.; Li D.; Abbruzzesse J.L.; Frazier M.L.; Killary A.M.; Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. 2009, 2, 807-813.
212. Kanaan Z.; Roberts H.; Eichenberger M.R.; Billeter A.; Ocheretner G.; Pan J.; Rai S.N.; Jorden J.; Williford A.; Galandiuk S. A plasma microRNA panel for detection of colorectal adenomas: A step toward more precise screening for colorectal cancer. Ann. Surg. 2013, 258, 400-408.
213. Teplyuk N.M.; Mollenhauer B.; Gabriely G.; Giese A.; Kim E.; Smolsky M.; Kim R.Y.; Saria M.G.; Pastorino S.; Kesari S.; et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncology 2012, 14, 689-700.
214. Baraniskin A.; Kuhnhenn J.; Schlegel U.; Maghnouj A.; Zollner H.; Schmiegel W.; Hahn S.; Schroers R. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology 2012, 14, 29-33.
215. Cho W.C. Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis. Front. Genet. 2011, 2, 7, doi:10.3389/fgene. 2011.00007.
216. De Smaele E.; Ferretti E.; Gulino A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res. 2010, 1338, 100-111.
217. Jin X.F.; Wu N.; Wang L.; Li J. Circulating microRNAs: A novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell. Mol. Neurobiol. 2013, 33, 601-613.
218. Chen S.Y.; Wang Y.; Telen M.J.; Chi J.T. The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One 2008, 3, e2360.
219. Wang K.; Zhang S.; Marzolf B.; Troisch P.; Brightman A.; Hu Z.; Hood L.E.; Galas D.J. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. USA 2009, 106, 4402-4407.
220. Cogswell J.P.; Ward J.; Taylor I.A.; Waters M.; Shi Y.; Cannon B.; Kelnar K.; Kemppainen J.; Brown D.; Chen C.; et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 2008, 14, 27-41.
221. Chen X.; Liang H.; Zhang J.; Zen K.; Zhang C.Y. Secreted microRNAs: A new form of intercellular communication. Trends Cell Biol. 2012, 22, 125-132.
222. Chin L.J.; Slack F.J. A truth serum for cancer-microRNAs have major potential as cancer biomarkers. Cell Res. 2008, 18, 983-984.
223. Mathivanan S.; Ji H.; Simpson R.J. Exosomes: Extracellular organelles important in intercellular communication. J. Proteomics 2010, 73, 1907-1920.
224. Valadi H.; Ekstrom K.; Bossios A.; Sjostrand M.; Lee J.J.; Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654-659.
225. Vickers K.C.; Palmisano B.T.; Shoucri B.M.; Shamburek R.D.; Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13, 423-433.
226. Hannafon B.N.; Ding W.Q. Intercellular Communication by Exosome-Derived microRNAs in Cancer. Int. J. Mol. Sci. 2013, 14, 14240-14269.
227. Mittelbrunn M.; Sanchez-Madrid F. Intercellular communication: Diverse structures for exchange of genetic information. Nat. Rev. Mol. Cell Biol. 2012, 13, 328-335.
228. Scaruffi P.; Stigliani S.; Moretti S.; Coco S.; de Vecchi C.; Valdora F.; Garaventa A.; Bonassi S.; Tonini G.P. Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 2009, 9, 441, doi:10.1186/1471-2407-9-441.
229. Creevey L.; Ryan J.; Harvey H.; Bray I.M.; Meehan M.; Khan A.R.; Stallings R.L. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol. Cancer 2013, 12, 23, doi:10.1186/1476-4598-12-23.
230. Vermeulen J.; de Preter K.; Mestdagh P.; Laureys G.; Speleman F.; Vandesompele J. Predicting outcomes for children with neuroblastoma. Discov. Med. 2010, 10, 29-36.
231. Northcott P.A.; Hielscher T.; Dubuc A.; Mack S.; Shih D.; Remke M.; Al-Halabi H.; Albrecht S.; Jabado N.; Eberhart C.G.; et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 2011, 122, 231-240.
232. Lu J.; Getz G.; Miska E.A.; Alvarez-Saavedra E.; Lamb J.; Peck D.; Sweet-Cordero A.; Ebert B.L.; Mak R.H.; Ferrando A.A.; et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
233. Zhao Z.; Moley K.H.; Gronowski A.M. Diagnostic potential for miRNAs as biomarkers for pregnancy-specific diseases. Clin. Biochem. 2013, 46, 953-960.
234. Gandellini P.; Profumo V.; Folini M.; Zaffaroni N. MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin. Ther. Targets 2011, 15, 265-79.
235. Li J.; Yuan X.; Liu J.; Li Y. Medulloblastoma Treatment using Gene Therapy. J. Gene Ther. 2013, 1, 6.
236. De Antonellis P.; Medaglia C.; Cusanelli E.; Andolfo I.; Liguori L.; de Vita G.; Carotenuto M.; Bello A.; Formiggini F.; Galeone A.; et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One 2011, 6, e24584.
237. Li K.K.; Pang J.C.; Lau K.M.; Zhou L.; Mao Y.; Wang Y.; Poon W.S.; Ng H.K. MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 2013, 23, 413-425.
238. Venkataraman S.; Birks D.K.; Balakrishnan I.; Alimova I.; Harris P.S.; Patel P.R.; Handler M.H.; Dubuc A.; Taylor M.D.; Foreman N.K.; et al. MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-Associated genes in medulloblastoma. J. Biol. Chem. 2013, 288, 1918-1928.
239. Bader A.G.; Brown D.; Stoudemire J.; Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011, 18, 1121-1126.
240. Bader A.G.; Brown D.; Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70, 7027-7030.
241. Krutzfeldt J.; Rajewsky N.; Braich R.; Rajeev K.G.; Tuschl T.; Manoharan M.; Stoffel M. Silencing of microRNAs in vivo with "antagomirs". Nature 2005, 438, 685-689.
242. Meister G.; Landthaler M.; Dorsett Y.; Tuschl T. Sequence-specific inhibition of microRNA-And siRNA-induced RNA silencing. RNA 2004, 10, 544-550.
243. Stenvang J.; Silahtaroglu A.N.; Lindow M.; Elmen J.; Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin. Cancer Biol. 2008, 18, 89-102.
244. Weiler J.; Hunziker J.; Hall J. Anti-miRNA oligonucleotides (AMOs): Ammunition to target miRNAs implicated in human disease? Gene Ther. 2006, 13, 496-502.
245. Zhu S.; Wu H.; Wu F.; Nie D.; Sheng S.; Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18, 350-359.
246. Gabriely G.; Wurdinger T.; Kesari S.; Esau C.C.; Burchard J.; Linsley P.S.; Krichevsky A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28, 5369-5380.
247. Moriyama T.; Ohuchida K.; Mizumoto K.; Yu J.; Sato N.; Nabae T.; Takahata S.; Toma H.; Nagai E.; Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 2009, 8, 1067-1074.
248. Bhardwaj A.; Singh S.; Singh A.P. MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol. Cell. Pharmacol. 2010, 2, 213-219.
249. Ebert M.S.; Neilson J.R.; Sharp P.A. MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4, 721-726.
250. Ebert M.S.; Sharp P.A. MicroRNA sponges: Progress and possibilities. RNA 2010, 16, 2043-2050.
251. Lu Y.; Xiao J.; Lin H.; Bai Y.; Luo X.; Wang Z.; Yang B. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res. 2009, 37, e24, doi:10.1093/nar/gkn1053.
252. Gentner B.; Schira G.; Giustacchini A.; Amendola M.; Brown B.D.; Ponzoni M.; Naldini L. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 2009, 6, 63-66.
253. Johnnidis J.B.; Harris M.H.; Wheeler R.T.; Stehling-Sun S.; Lam M.H.; Kirak O.; Brummelkamp T.R.; Fleming M.D.; Camargo F.D. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008, 451, 1125-1129.
254. Xiao J.; Yang B.; Lin H.; Lu Y.; Luo X.; Wang Z. Novel approaches for gene-specific interference via manipulating actions of microRNAs: Examination on the pacemaker channel genes HCN2 and HCN4. J. Cell. Physiol. 2007, 212, 285-292.
255. Takamizawa J.; Konishi H.; Yanagisawa K.; Tomida S.; Osada H.; Endoh H.; Harano T.; Yatabe Y.; Nagino M.; Nimura Y.; et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64, 3753-3756.
256. Trang P.; Medina P.P.; Wiggins J.F.; Ruffino L.; Kelnar K.; Omotola M.; Homer R.; Brown D.; Bader A.G.; Weidhaas J.B.; et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29, 1580-1587.
257. Kota J.; Chivukula R.R.; O'Donnell K.A.; Wentzel E.A.; Montgomery C.L.; Hwang H.W.; Chang T.C.; Vivekanandan P.; Torbenson M.; Clark K.R.; et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017.
258. Wiggins J.F.; Ruffino L.; Kelnar K.; Omotola M.; Patrawala L.; Brown D.; Bader A.G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70, 5923-5930.
259. Ibrahim A.F.; Weirauch U.; Thomas M.; Grunweller A.; Hartmann R.K.; Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011, 71, 5214-5224.
260. Takeshita F.; Patrawala L.; Osaki M.; Takahashi R.U.; Yamamoto Y.; Kosaka N.; Kawamata M.; Kelnar K.; Bader A.G.; Brown D.; et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18, 181-187.
261. Cimmino A.; Calin G.A.; Fabbri M.; Iorio M.V.; Ferracin M.; Shimizu M.; Wojcik S.E.; Aqeilan R.I.; Zupo S.; Dono M.; et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102, 13944-13949.
262. Calin G.A.; Dumitru C.D.; Shimizu M.; Bichi R.; Zupo S.; Noch E.; Aldler H.; Rattan S.; Keating M.; Rai K.; et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 15524-15529.
263. Bonci D.; Coppola V.; Musumeci M.; Addario A.; Giuffrida R.; Memeo L.; D'Urso L.; Pagliuca A.; Biffoni M.; Labbaye C.; et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14, 1271-1277.
264. Li C.; Feng Y.; Coukos G.; Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J. 2009, 11, 747-757.
265. Garzon R.; Marcucci G.; Croce C.M. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat. Rev. 2010, 9, 775-789.
266. Deeken J.F.; Loscher W. The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007, 13, 1663-1674.